CD274 and head and neck squamous cell carcinoma: This confirms firstly that therapeutic targeting of the PD‐1/PD‐L1 axis in HNSCC is a potential treatment option which has been confirmed in multiple landmark studies using PD‐1/PD‐L1 inhibitors in biomarker selected and unselected patients.1, 2